Dmt-Usa Inc.

Dmt-Usa Inc., an Ann Arbor, Michigan–based for-profit small business, manufactures and delivers specialized biomedical research instrumentation—pressure myograph systems, organ bath systems, and automated microtomes—to the National Institutes of Health and the Department of Veterans Affairs as a sole-source prime contractor. The vendor operates exclusively in the full-and-open market (39 awards, 100% prime; no set-asides across the footprint), competing on technical specification and established sole-source authority across NIH and VA research networks.

Dmt-Usa Inc.'s capability portfolio centers on ex vivo vascular and tissue-function assessment equipment. Recent representative work includes a $46,630 purchase order from the National Heart, Lung, and Blood Institute (September 2026) for a DMT pressure myograph system with integrated longitudinal force transducers, pressure transducers, and real-time vessel-diameter tracking software; a $57,300 order from NHLBI (August 2023) for a Leica autocut microtome with silver service; a $43,130 VA purchase order (September 2023) for a pressure myograph system to support VA Ann Arbor medical center research; and a $41,453 National Institute on Drug Abuse award (September 2023) for organ bath and myograph service and maintenance. NHLBI's technical assessment for the 2026 award confirmed that Dmt-Usa Inc. is the sole source capable of providing an integrated pressure myograph with the required longitudinal force-measurement capability; competing systems lack the integrated combination of vessel-size flexibility, force measurement, integrated pressure transducers, microscopy integration, and compatible real-time software.

Customer concentration sits with research-intensive components of HHS and VA. The National Heart, Lung, and Blood Institute accounts for 7 awards and $307 thousand combined potential value; VA Veterans Integrated Service Network 19 carries 6 awards and $281 thousand. These two customers represent 49% of awards and 56% of combined potential value. The vendor has served 20 distinct customer agencies across the portfolio, but activity is sparse and episodic—one award in 2024, one in 2025, and one in 2026, following five awards in 2023. Combined obligated value across all 39 awards totals $1.6 million, with only one award (the September 2026 NHLBI order valued at $47 thousand) reaching ultimate completion within the next twenty-four months, exposing limited recompete pressure. Dmt-Usa Inc. operates no parent vehicles, team relationships, or sub-award footprint; it functions as a standalone equipment supplier dependent on direct purchase orders and sole-source procurement authority within NIH and VA networks.